Astria Therapeutics, Inc. (ATXS) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boston, MA, 美国. 现任CEO为 Jill C. Milne.
ATXS 拥有 IPO日期为 2015-06-25, 78 名全职员工, 在 NASDAQ Global Market, 市值为 $718.13M.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
